FAKTOR OPTIONSSCHEIN - ROCHE GS Share Price

Certificat

DE000GB2ZFP0

Market Closed - BOERSE MUENCHEN 19:26:32 20/06/2024 BST
3.54 EUR +0.20% Intraday chart for FAKTOR OPTIONSSCHEIN - ROCHE GS
Current month+28.12%
1 month+19.47%
Date Price Change
20/06/24 3.54 +0.20%
19/06/24 3.533 +1.52%
18/06/24 3.48 +2.65%
17/06/24 3.39 -1.17%
14/06/24 3.43 +1.78%

Real-time BOERSE MUENCHEN

Last update June 20, 2024 at 07:26 pm

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Goldman Sachs
WKN GB2ZFP
ISINDE000GB2ZFP0
Date issued 23/09/2019
Strike 166.5 CHF
Maturity Unlimited
Parity 24.8 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 18.94
Lowest since issue 2.243
Spread 0.02
Spread %0.56%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
250 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.22%
Consensus